{"filings":[{"id":95646,"accession_number":"0001808805-26-000015","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology Q1 loss narrows to $14.7M; cash $143.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.7M vs $16.6M in Q1 2025; operating expenses down 14% YoY to $16.1M.","Cash, equivalents, and investments total $143.4M as of March 31, 2026.","Launched Iterative Mapping Early Access Program; Baylor College of Medicine first customer for Tau proteoform assay in NIH-funded cancer study.","Appointed Amber Faust as VP of Global Sales, a commercial leader from Olink and SomaLogic."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108845,"accession_number":"0001808805-26-000004","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology FY2025 net loss narrows to $59M; cash $156M; guidance for higher 2026 spend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss of $13.8M vs $17.6M YoY; operating expenses down 23% to $15.4M.","FY2025 net loss of $59.0M vs $70.8M in FY2024; operating expenses fell 18% to $66.8M.","Cash and investments $156.1M as of Dec 31, 2025; management sees sufficient runway through 2027.","Early Access Program launched Jan 2026 for Tau proteoforms; no material revenue expected in FY2026.","FY2026 operating expenses expected to increase 15-20% YoY; full commercial launch targeted late 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125305,"accession_number":"0001808805-25-000082","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nautilus regains Nasdaq minimum bid price compliance; deficiency closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice on Nov 3, 2025 that closing bid price met $1 for 10 consecutive days.","Deficiency previously disclosed May 2, 2025; compliance period extended to April 27, 2026.","Company transferred to Nasdaq Capital Market on Oct 29, 2025 to utilize second compliance period.","Matter now closed; no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125304,"accession_number":"0001808805-25-000077","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology Q3 2025 net loss $13.6M; operating expenses down 19% to $15.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.6M for Q3 2025, improved from $16.4M loss in Q3 2024.","Operating expenses $15.5M, down 19% from $19.1M year-over-year.","Cash and investments $168.5M as of Sept 30, 2025.","Progress on Tau proteoform samples; early access program expected H1 2026; commercial launch late 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142021,"accession_number":"0001808805-25-000069","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Q2 net loss narrows to $15.0M; cash $179.5M; platform milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating expenses $17.1M, down 18% YoY from $20.8M.","Net loss $15.0M improved from $18.0M loss in Q2 2024.","Cash, equivalents and investments $179.5M as of June 30, 2025.","Published first scientific manuscript validating Iterative Mapping method for proteoform measurement.","Signed two collaborations to study Tau proteoforms in Alzheimer's disease."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159989,"accession_number":"0001808805-25-000054","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nautilus Biotechnology elects Class I directors, ratifies PwC, reduces board size to 7","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sujal Patel re-elected with 84.3M votes for; Matthew McIlwain elected with 82.2M votes for.","PricewaterhouseCoopers LLP ratified as auditor for 2025 with 99.5M votes for.","Board reduced from 9 to 7 directors effective after annual meeting.","Directors Vijay Pande and Michael Altman did not stand for re-election; McIlwain resigned as Class II to stand for Class I."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159988,"accession_number":"0001808805-25-000047","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nautilus Biotechnology receives Nasdaq bid price deficiency notice; has until Oct 28, 2025 to regain compliance.","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice on May 1, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive business days through April 30, 2025.","Has 180 calendar days (until October 28, 2025) to regain compliance; stock continues trading.","To cure, closing bid price must be at least $1.00 for ten consecutive business days during the Compliance Period.","If not compliant, may qualify for additional 180 days by transferring to Nasdaq Capital Market and meeting other requirements.","No immediate delisting; company evaluating options but no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159987,"accession_number":"0001808805-25-000039","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Q1 net loss $16.6M, operating expenses down 13% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.6M, improved from $18.7M in Q1 2024.","Operating expenses $18.8M, down 13% from $21.6M prior year.","Cash, equivalents, and investments $192.8M as of March 31, 2025.","CEO reports progress on Tau proteoform assay toward commercial launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178314,"accession_number":"0001808805-25-000004","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology reports Q4 net loss $17.6M; platform launch delayed to late 2026; headcount cut 16%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 operating expenses flat at $20.0M; FY2024 op. expenses $81.5M (+7% YoY).","Net loss Q4 $17.6M vs $17.0M YoY; FY2024 net loss $70.8M vs $63.7M YoY.","Proteome analysis platform commercial launch now expected late 2026 (previously undisclosed).","Headcount reduced ~16% to extend cash runway; cash $206.3M expected to fund operations through 2027.","Board changes: two directors not standing for re-election; Matthew McIlwain reclassified as Class I director; board size reduced to 7."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178313,"accession_number":"0001808805-25-000002","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two Nautilus Biotechnology directors not standing for re-election at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vijay Pande informed company on Jan 27, 2025, that he will not stand for re-election.","Michael Altman informed company on Jan 28, 2025, that he will not stand for re-election.","Both directors confirmed departure is not due to any disagreement with company operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194973,"accession_number":"0001808805-24-000070","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Q3 net loss $16.4M, cash $221.2M; OpEx flat YoY at $19.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.4M for Q3 2024, compared to $15.9M loss in Q3 2023.","Operating expenses $19.1M, flat YoY; personnel cost increase offset by incentive accrual reduction.","Cash, equivalents, and investments totaled $221.2M as of September 30, 2024.","CEO notes positive researcher feedback for single-molecule proteome platform, no revenue reported."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211267,"accession_number":"0001808805-24-000055","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Biotechnology reports Q2 2024 net loss of $18M, operating expenses up 9% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.0M in Q2 2024 vs $15.8M in Q2 2023.","Operating expenses of $20.8M, up $1.8M or 9% from $19.0M a year ago.","Cash, equivalents, and investments of $232.9M as of June 30, 2024.","Expense increase driven by higher headcount to support product development.","Company continues development of single-molecule proteome analysis platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229825,"accession_number":"0001808805-24-000043","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nautilus Biotechnology announces 2024 annual meeting voting results","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Melissa Epperly (92.1M for, 674K withheld), Matthew L. Posard (90.6M for, 2.1M withheld), Karen Akinsanya (89.9M for, 2.8M withheld) as Class III directors.","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2024 with 105.1M votes for, 172.9K against, 69.2K abstentions.","Approximately 84% of outstanding shares (105.3M of 125.3M) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229824,"accession_number":"0001808805-24-000038","cik":1808805,"company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nautilus Q1 net loss $18.7M vs $15.0M YoY; cash $247.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.7M widened from $15.0M in Q1 2023; no revenue reported.","Operating expenses $21.6M, up 20% YoY on higher headcount for platform development.","Cash, equivalents and investments $247.7M as of March 31, 2024.","CEO cites progress on consumables, assay, instrument and software scale/reproducibility."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":338029732.6875,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}